EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events associated with benznidazole treatment for Chagas disease in children and adults

Cintia Valeria Cruz iD, Andres Rabinovich, Guillermo Moscatelli, Samanta Moroni, Nicolas González, Facundo Garcia-Bournissen iD, Griselda Ballering, Hector Freilij, Jaime Altcheh iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Cintia Valeria Cruz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Parasitología y Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Ricardo …. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Trypanocidal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, This work was partially funded by Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chagas disease (ChD) affects approximately 7 million people in Latin America, with benznidazole being the most commonly used treatment.

Methods

Data from a retrospective cohort study in Argentina, covering January 1980 to July 2019, was reanalysed to identify and characterize benznidazole‐related adverse drug reactions (ADRs).

Results

The study included 518 patients: 449 children and 69 adults (median age in children: 4 years; adults: 25 years; age ranges: 1 month–17.75 years and 18–59 years, respectively). The median benznidazole doses received were 6.6 mg/kg/day for at least 60 days in children and 5.6 mg/kg/day for a median of 31 days in adults. Overall, 29.34% (152/518) of patients developed benznidazole‐related ADRs, with an incidence of 25.83% (116/449) in children and 52.17% (36/69) in adults (odds ratio [OR] = 0.32, 95% confidence interval [CI] = 0.19–0.54, P < .001). The incidence rate was 177 cases per 1000 person‐years (95% CI = 145–214) in children and 537 per 1000 person‐years (95% CI = 360–771) in adults. There were 240 ADRs identified, primarily mild to moderate. Severe ADRs occurred in 1.11% (5/449) of children and 1.45% (1/69) of adults. The skin was the most affected system. A total of 10.23% (53/518) of patients discontinued treatment. More adults than children discontinued treatment (OR = 3.36, 95% CI = 1.7–6.4, P < .001).

Conclusions

Although 29.34% of patients experienced ADRs, most were mild to moderate, indicating a manageable safety profile for benznidazole. While optimized dosing schedules and new drugs are needed, avoiding benznidazole solely due to safety concerns is not justified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesChagas DiseaseTrypanocidal AgentsHumansChildAdolescentAdultMaleRetrospective StudiesFemaleChild, PreschoolMiddle AgedYoung AdultArgentinaInfantIncidence

Stichwörter der Autor:innen

Chagas diseaseTrypanosoma cruziadultsadverse drug reactionsbenznidazolechildrencongenital

Substanzen

benzonidazoleNitroimidazolesTrypanocidal Agents

Autor:innen und Institutionen

  • Servicio de Parasitología y Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
  • Mahidol Oxford Research Unit (MORU), Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

ORCID-Profile: Cintia Valeria Cruz, Facundo Garcia-Bournissen, Jaime Altcheh

Förderung

  • Wellcome Trust
  • This work was partially funded by Wellcome Trust

Zitieren

APA

Cruz, C. V., Rabinovich, A., Moscatelli, G., Moroni, S., González, N., Garcia-Bournissen, F., Ballering, G., Freilij, H., & Altcheh, J. (2024). Adverse events associated with benznidazole treatment for Chagas disease in children and adults. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16214

Vancouver

Cruz CV, Rabinovich A, Moscatelli G, Moroni S, González N, Garcia-Bournissen F, et al. Adverse events associated with benznidazole treatment for Chagas disease in children and adults. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16214

BibTeX
@article{Cruz2024,
  author = {Cruz, Cintia Valeria and Rabinovich, Andres and Moscatelli, Guillermo and Moroni, Samanta and González, Nicolas and Garcia-Bournissen, Facundo and Ballering, Griselda and Freilij, Hector and Altcheh, Jaime},
  title = {Adverse events associated with benznidazole treatment for Chagas disease in children and adults},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16214}
}
Kostenlos starten →